



MINNESOTA BOARD OF PHARMACY

newsletter to promote pharmacy and drug law compliance

Disciplinary Actions Listed Online

Because of space limitations, information on disciplinary actions is no longer included in the *Minnesota Board of Pharmacy Newsletter*. A document that provides information about recent Board disciplinary actions can be found on the Board's [website](#) under the "Resources/FAQs" menu item.

Board Member Appointments

Governor Tim Walz has reappointed Amy Paradis as a pharmacist member of the Board. Dr Paradis has been a member of the Board since July 2017. She practices pharmacy in Worthington, MN, and has experience in long-term care and hospital pharmacy.

Governor Walz has appointed Michael Haag to be a pharmacist member of the Board, replacing Mary Phipps. Dr Haag graduated from the University of Minnesota College of Pharmacy in 2000 and has a background in retail and specialty pharmacies, compounding, sterile product handling, and managed care.

PMP Audits

The Minnesota Prescription Monitoring Program (PMP) recently updated two audit processes for qualifying users to complete on a quarterly basis. These auditing requirements are intended to ensure that access to PMP data is in accordance with Minnesota Statutes Section 152.126.

Delegate Audit

If you have authorized [delegate\(s\)](#), you are required to review the searches they performed under your authority on at least a quarterly basis. Notifications are sent from

National Pharmacy Compliance News

A Service of the National Association of Boards of Pharmacy Foundation (NABPF)

Visit NABP's website for the latest regulatory updates and news from FDA, USP, NABP, and more.

[Read National News](#)

the PMP via email when the auditing period is open (the first day of the next quarter), along with instructions describing how to complete the audit. Users can log in to the [Minnesota PMP web portal](#) to review each delegate's search history. If you have not had any searches performed by a delegate during the quarter, you will not receive the notification email and no action is required on your part.

Random Audit

Each quarter, a selection of [account holders](#) will be chosen at random to review their search history for compliance with permissible use of the Minnesota PMP as outlined in Minnesota Statutes §152.126.6(b).

If your account is randomly selected for an audit, a notification with instructions will be sent to the email address on your Minnesota PMP account. The account holder must review their Minnesota PMP searches that occurred during the time frame indicated in the notification. The review should verify compliance with Minnesota Statutes §152.126.6(b). A survey attestation link is provided in the email to complete the audit and must be completed within 30 days of initial notification. Those who fail to complete the audit may have their account deactivated and be referred to their respective health licensing board for review.

If you receive a communication regarding an audit from the Minnesota PMP, it is recommended that you follow and complete the instructions included at your earliest convenience. If you have questions, please contact the Minnesota PMP staff at minnesota.pmp@state.mn.us.

Xylazine

Xylazine is a non-opioid animal sedative and tranquilizer. Xylazine has been found in the illicit drug supply in combination with forms of fentanyl and other drugs, such as heroin and cocaine; this occurrence has become increasingly prominent. Xylazine-involved overdose deaths are rising across the country. [Food and Drug Administration](#) has taken action to restrict the unlawful import of xylazine. Information specific to Minnesota can be found on the Minnesota Department of Health [website](#). The Centers for Disease Control and Prevention has also published information regarding management of [drug overdoses](#), including those that involve xylazine.

The Minnesota Board of Pharmacy News is published by the Minnesota Board of Pharmacy and the National Association of Boards of Pharmacy Foundation® (NABPF®) to promote compliance of pharmacy and drug law. The opinions and views expressed in this publication do not necessarily reflect the official views, opinions, or policies of NABPF or the Board unless expressly so stated.

Jill Phillips, MPH, RPh - State News Editor

Lemrey "Al" Carter, PharmD, MS, RPh - National News Editor & Executive Editor

Megan Pellegrini - Publications and Editorial Manager

335 Randolph Avenue, Suite 230 | St Paul, MN 55102 | <https://mn.gov/boards/pharmacy>